Oxidative stress markers in hemodialysis and peritoneal dialysis patients, including coenzyme Q10 and ischemia-modified albumin

International Journal of Artificial Organs

Volumn 35, Issue 3, 2012, Pages 226-232

  Mehmetoglu, Idris ^a   Humeyra Yerlikaya F ^a   Kurban, Sevil ^a   Sami Erdem, S ^a   Tonbul, Zeki ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Continuous ambulatory peritoneal dialysis; Hemodialysis; Ischemiamodified albumin; Total antioxidant status; Total oxidant status

Indexed keywords

ANTIOXIDANTS; BODY FLUIDS; CHOLESTEROL; COENZYMES; FREE RADICALS; HEMODIALYZERS; LIPIDS; OXIDANTS; OXIDATIVE STRESS;

COENZYME Q; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HAEMODIALYSIS; HEMODIALYSIS PATIENT; ISCHAEMIA; ISCHEMIAMODIFIED ALBUMIN; PERITONEAL DIALYSIS; TOTAL ANTIOXIDANT STATUS; TOTAL CHOLESTEROLS; TOTAL OXIDANT STATUS;

DIALYSIS;

ANTIOXIDANT; CHOLESTEROL; ISCHEMIA MODIFIED ALBUMIN; TRIACYLGLYCEROL; UBIDECARENONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LIPID BLOOD LEVEL; MALE; OXIDATIVE STRESS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862736322     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000078     Document Type: Article

References (29)

1. Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M. Oxidative stress and ferritin levels in hemodialysis patients. Nephrol Dial Transplant. 2008;23(2):665-672. Medline. doi:10.1093/ndt/gfm588
2. Mayer B, Zitta S, Greilberger J, et al. Effect of hemodialysis on the antioxidative properties of serum. Biochim Biophys Acta. 2003;1638(3):267-272.
3. Horoz M, Aslan M, Koylu AO, et al. The relationship between leptin level and oxidative status parameters in hemodialysis patients. Artif Organs. 2009;33(1):81-85. Medline. doi:10.1111/j.1525-1594.2008.00678.x
4. Aslan M, Sabuncu T, Kocygit A, Celik H, Selek S. Relationship between total oxidant status and severity of diabetic nephropathy in type 2 diabetic patients. Nutr Metab Cardiovasc Dis. 2007;17(10):734-740. Medline. doi:10.1016/j.numecd.2006.08.005
5. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37(2):112-119. Medline. doi:10.1016/j.clinbiochem.2003.10.014
6. Singh RB, Khanna HK, Niaz MA. Randomized, doubleblindplacebo-controlled trial of coenzyme Q10 in chronic renal failure: discovery of a new role. J Nutr Environ Med. 2000;10:281-288. doi:10.1080/13590840020013266
7. Lippa S, Colacicco L, Callà C, Sagliaschi G, Angelitti AG. Coenzyme Q10 levels, plasma lipids and peroxidation extent in renal failure and in hemodialytic patients. Mol Aspects Med. 1994;15:213-219. doi:10.1016/0098-2997(94)90031-0
8. Carrega L, Giaime P, Montserrat C, et al. Influence of the dialysis membrane on markers of tissue ischemia. J Investig Med. 2006;54(2):62-66. Medline. doi:10.2310/6650.2005.05033
9. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as marker its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med. 2000;19(4):311-315. Medline. doi:10.1016/S0736-4679(00)00255-9
10. Cichota LC, Moresco RN, Duarte MM, da Silva JE. Evaluation of ischemia-modified albumin in anemia associated to chronic kidney disease. J Clin Lab Anal. 2008;22(1):1-5. Medline. doi:10.1002/jcla.20226
11. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart. 2006;92(1):113-114. Medline. doi:10.1136/hrt.2004.049643
12. Valle Gottlieb MG, da Cruz IB, Duarte MM, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95(2):586-591. Medline. doi:10.1210/jc.2009-1592
13. Kaefer M, Piva SJ, De Carvalho JA, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem. 2010;43(4-5):450-454. Medline. doi:10.1016/j.clinbiochem.2009.11.018
14. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-1111. Medline. doi:10.1016/j.clinbiochem.2005.08.008
15. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischaemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med. 2007;45(2):261-262. Medline. doi:10.1515/CCLM.2007.039
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
17. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41(8 Pt 1):1135-1138.
18. Mircescu G, Capuşǎ C, Stoian I, Vârgolici B, Barbulescu C, Ursea N. Global assessment of serum antioxidant status in hemodialysis patients. J Nephrol. 2005;18(5):599-605.
19. Usberti M, Gerardi GM, Gazzotti RM, et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron. 2002;91(1):25-33. Medline. doi:10.1159/000057601
20. Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol. 2003;35(3):393-397. Medline. doi:10.1023/B:UROL.0000022846.83505.3f
21. Jung HH, Han H, Lee JH. Sleep apnea, coronary artery disease, and antioxidant status in hemodialysis patients. Am J Kidney Dis. 2005;45(5):875-882. Medline. doi:10.1053/j.ajkd.2005.01.006
22. Abdel-Naeem NM, Kandell NF, El-Shamaa AA, Harba TM, Abdel-Hady AA. Biocompatible dialysis membranes and oxidative stress in patients with end-stage renal disease on maintenance haemodialysis. J Egypt Soc Parasitol. 2005;35(3) (Suppl):1173-1197.
23. Bibi G, Green Y, Nagler RM. Compositional and oxidative analysis in the saliva and serum of predialysis chronic kidney disease patients and end-stage renal failure patients on peritoneal dialysis. Ther Apher Dial. 2008;12(2):164-170. Medline. doi:10.1111/j.1744-9987.2008.00564.x
24. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired Antioxidant Activity of HDL in Chronic Kidney Disease. Transl Res. 2009;153:77-85. Medline. doi:10.1016/j.trsl.2008.11.007
25. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287-296. Medline. doi:10.1038/nrneph. 2010.36
26. McDonnell MG, Archbold GP. Plasma ubiquinol/cholesterol ratios in patients with hyperlipidaemia, those with diabetes mellitus and in patients requiring dialy sis. Clin Chim Acta. 1996;253(1-2):117-126. Medline. doi:10.1016/0009-8981(96)06357-7
27. Lippa S, Colacicco L, Bondanini F, et al. Plasma levels of coenzyme Q(10), vitamin E and lipids in uremic patients on conservative therapy and hemodialysis treatment: some possible biochemical and clinical implications. Clin Chim Acta. 2000;292(1-2):81-91. Medline. doi:10.1016/S0009-8981(99)00204-1
28. Turedi S, Cinar O, Yavuz I, et al. Differences in ischemia- modified albumin levels between end stage renal disease patients and the normal population. J Nephrol. 2010;23(3):335-340.
29. Montagnana M, Lippi G, Tessitore N, et al. Effect of hemodialysis on traditional and innovative cardiac markers. J Clin Lab Anal. 2008;22(1):59-65. Medline. doi:10.1002/jcla.20210